Tylan Soluble Powder for Oral Solution

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Tylosin Tartrate

Disponible desde:

Elanco Europe Ltd

Código ATC:

QJ01FA90

Designación común internacional (DCI):

Tylosin Tartrate

formulario farmacéutico:

Powder for oral solution

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cattle, Chickens, Pigs, Turkeys

Área terapéutica:

Antimicrobial

Estado de Autorización:

Authorized

Fecha de autorización:

1993-05-25

Ficha técnica

Revised: September 2020
AN: 00822/2020
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Tylan Soluble Powder for Oral Solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tylosin 100g activity per bottle as Tylosin Tartrate.
Tylosin 1000g activity per bag Tylosin Tartrate.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for oral solution
A white to medium yellow powder.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
For use in calves, pigs, chickens and turkeys .
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of _Mycoplasma synoviae_ airsacculitis in chickens and
_Mycoplasma gallisepticum_ S6 in chickens and turkeys. In the field
tylosin
has also proved useful in reducing the level of infection following
stress
associated with live vaccination.
As an aid in the control of outbreaks of necrotic enteritis in
chickens caused
by _Clostridium perfringens_.
For the prevention and control of enzootic pneumonia, and scours
caused
by organisms (e.g. _Lawsonia intracellularis_) sensitive to tylosin,
in pigs.
For the control of pneumonia in cattle associated with mycoplasmata
and
_Pasteurella multocida_ sensitive to tylosin.
For information regarding swine dysentery see section 4.5.
Revised: September 2020
AN: 00822/2020
Page 2 of 8
4.3
CONTRAINDICATIONS
Do not leave or dispose of water containing tylosin tartrate where it
may be
accessible to either animals not under treatment or to wildlife.
Do not use in known cases of hypersensitivity to tylosin or other
macrolides.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
4.5
SPECIAL PRECAUTIONS FOR USE
i)
Special precautions for use in animals
Use of the product should be based on susceptibility testing of the
bacteria isolated from the animal. If this is not possible, therapy
should be based on local (regional, farm level) epidemiological
information about susceptibility of the target bacteria.
Official, national and regional antimicrobial policies should be taken
in